NASDAQ:SPRB - Nasdaq - US85209E1091 - Common Stock - Currency: USD
0.0786
-0.05 (-39.45%)
The current stock price of SPRB is 0.0786 USD. In the past month the price decreased by -73.37%. In the past year, price decreased by -89.44%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.33 | 351.09B | ||
AMGN | AMGEN INC | 13.55 | 151.20B | ||
GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.56B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
NTRA | NATERA INC | N/A | 21.18B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
BIIB | BIOGEN INC | 7.81 | 18.10B |
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company is headquartered in South San Francisco, California and currently employs 21 full-time employees. The company went IPO on 2020-10-09. The firm has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The firm's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.
SPRUCE BIOSCIENCES INC
611 Gateway Boulevard, Suite 740
South San Francisco CALIFORNIA 94104 US
CEO: Richard King
Employees: 22
Company Website: https://sprucebio.com/
Investor Relations: https://investors.sprucebiosciences.com/
Phone: 14156554168
The current stock price of SPRB is 0.0786 USD. The price decreased by -39.45% in the last trading session.
The exchange symbol of SPRUCE BIOSCIENCES INC is SPRB and it is listed on the Nasdaq exchange.
SPRB stock is listed on the Nasdaq exchange.
10 analysts have analysed SPRB and the average price target is 1.53 USD. This implies a price increase of 1846.56% is expected in the next year compared to the current price of 0.0786. Check the SPRUCE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SPRUCE BIOSCIENCES INC (SPRB) has a market capitalization of 3.32M USD. This makes SPRB a Nano Cap stock.
SPRUCE BIOSCIENCES INC (SPRB) currently has 22 employees.
The Revenue of SPRUCE BIOSCIENCES INC (SPRB) is expected to decline by -68.59% in the next year. Check the estimates tab for more information on the SPRB EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SPRB does not pay a dividend.
SPRUCE BIOSCIENCES INC (SPRB) will report earnings on 2025-05-12, after the market close.
SPRUCE BIOSCIENCES INC (SPRB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.28).
The outstanding short interest for SPRUCE BIOSCIENCES INC (SPRB) is 1.37% of its float. Check the ownership tab for more information on the SPRB short interest.
ChartMill assigns a fundamental rating of 1 / 10 to SPRB. SPRB has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months SPRB reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS decreased by -1.59% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -117.31% | ||
ROE | -184.02% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 50% to SPRB. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 54.58% and a revenue growth -68.59% for SPRB